Faculty

Back to Index
Guy A. Young, MD
Professor of Pediatrics (Clinical Scholar)
Pediatrics
CHL Mail Stop 54 Off Campus Los Angeles
+1 323 361 4628

Overview

Following medical school, I completed my residency in pediatrics at Schneider Children's Hospital-Long Island Jewish Medical Center which is part of the Albert Einstein College of Medicine. I then completed a fellowship in pediatric hematology/oncology at Children's National Medical Center in Washington, DC which is part of the George Washington University School of Medicine. I then began my research career at the Children's Hospital of Orange County under the mentorship of Dr. Diane Nugent. There, I became interested in improving the treatment for patients with hemophilia and inhibitors and for children with blood clots. I received my first independent grants there inculding a grant from the FDA to study a new anticoagulant in children. In addition, I became interested in thromboelastography. In 2007, I moved the Children's Hospital Los Angeles where I am continuing to perform research in the same areas as I had started in Orange County.

Awards

National Hemophilia Foundation: Physician of the Year, 2013

Publications

How I treat pediatric venous thromboembolism. Blood. 2017 Sep 21; 130(12):1402-1408. View in: PubMed

Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studies and registries. Am J Hematol. 2017 Sep; 92(9):940-945. View in: PubMed

How I treat pediatric venous thromboembolism. Blood. 2017 Aug 03. View in: PubMed

Pediatric Anticoagulation: Time for a New Paradigm? J Pediatr. Pediatric Anticoagulation: Time for a New Paradigm? J Pediatr. 2017 Jul 10. View in: PubMed

Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates. Thromb Haemost. 2017 Jun 02; 117(6):1023-1030. View in: PubMed

Anticoagulation in children: Making the most of little patients and little evidence. Blood Cells Mol Dis. 2017 May 06. View in: PubMed

Thromboelastographic characterization of the activated clotting system in children with sickle cell trait or sickle cell disease. Thromb Res. 2017 Mar; 151:44-50. View in: PubMed

Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017 08 31; 377(9):809-818. View in: PubMed

Impact of high-risk thrombophilia status on recurrence among children with a first non-central-venous-catheter-associated VTE: an observational multicentre cohort study. Br J Haematol. 2016 Oct; 175(1):133-40. View in: PubMed

The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016 Jul 09; 388(10040):187-97. View in: PubMed

Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thromb Haemost. 2016 Jul 04; 116(1):1-8. View in: PubMed

A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016 May 26; 374(21):2054-64. View in: PubMed

Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4). Thromb Res. 2016 May; 141:69-76. View in: PubMed

The bleeding newborn: A review of presentation, diagnosis, and management. Semin Fetal Neonatal Med. 2016 Feb; 21(1):44-9. View in: PubMed

The perils of rivaroxaban in younger patients. Thromb Res. 2016 12; 148:154-155. View in: PubMed

Global assays in hemophilia. Semin Hematol. 2016 Jan; 53(1):40-5. View in: PubMed

Anticoagulants in children and adolescents. Hematology Am Soc Hematol Educ Program. 2015; 2015:111-6. View in: PubMed

Understanding patient preferences and willingness to pay for hemophilia therapies. Patient Prefer Adherence. 2015; 9:1623-30. View in: PubMed

Evaluation of algorithms for the treatment of problem bleeding episodes in patients with hemophilia having inhibitors. Clin Appl Thromb Hemost. 2015 Jan; 21(1):10-8. View in: PubMed

Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood. 2014 Dec 18; 124(26):3880-6. View in: PubMed

FondaKIDS II: long-term follow-up data of children receiving fondaparinux for treatment of venous thromboembolic events. Thromb Res. 2014 Sep; 134(3):643-7. View in: PubMed

Developmental hemostasis: clinical implications from the fetus to the adolescent. Pediatr Clin North Am. 2013 Dec; 60(6):1407-17. View in: PubMed

Incidence of thrombosis in children with tunneled central venous access devices versus peripherally inserted central catheters (PICCs). Thromb Res. 2013 Nov; 132(5):527-30. View in: PubMed

Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients. Clin Pharmacokinet. 2013 Nov; 52(11):967-80. View in: PubMed

Antithrombin III administration in neonates with congenital diaphragmatic hernia during the first three days of extracorporeal membrane oxygenation. J Pediatr Surg. 2013 Sep; 48(9):1837-42. View in: PubMed

A novel approach for detecting hypercoagulability utilizing thromboelastography. Thromb Res. 2013 Apr; 131(4):352-6. View in: PubMed

Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood. 2013 Mar 14; 121(11):1944-50. View in: PubMed

Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol. 2013 Feb; 4(1):59-72. View in: PubMed

PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors. Thromb Res. 2012 Dec; 130(6):864-70. View in: PubMed

Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008). Haemophilia. 2012 Nov; 18(6):990-6. View in: PubMed

Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A. Am J Hematol. 2012 Sep; 87(9):933-6. View in: PubMed

From boy to man: recommendations for the transition process in haemophilia. Haemophilia. 2012 Jul; 18 Suppl 5:27-32. View in: PubMed

Pharmacokinetic- and pharmacodynamic-based antithrombotic dosing recommendations in children. Expert Rev Clin Pharmacol. 2012 Jul; 5(4):389-96. View in: PubMed

Difficult clinical challenges in haemophilia: international experiential perspectives. Haemophilia. 2012 Jul; 18 Suppl 5:39-45. View in: PubMed

Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE). Haemophilia. 2012 May; 18(3):392-9. View in: PubMed

Capturing daily assessments and home treatment of congenital hemophilia with inhibitors: design, disposition, and implications of the Dosing Observational Study in Hemophilia (DOSE). J Blood Med. 2012; 3:131-8. View in: PubMed

New challenges in hemophilia: long-term outcomes and complications. Hematology Am Soc Hematol Educ Program. 2012; 2012:362-8. View in: PubMed

FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age. Pediatr Blood Cancer. 2011 Dec 01; 57(6):1049-54. View in: PubMed

Old and new antithrombotic drugs in neonates and infants. Semin Fetal Neonatal Med. 2011 Dec; 16(6):349-54. View in: PubMed

Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. Semin Thromb Hemost. 2011 Oct; 37(7):802-9. View in: PubMed

When should prophylaxis therapy in inhibitor patients be considered? Haemophilia. When should prophylaxis therapy in inhibitor patients be considered? Haemophilia. 2011 Sep; 17(5):e849-57. View in: PubMed

Modeling costs and outcomes associated with a treatment algorithm for problem bleeding episodes in patients with severe hemophilia a and high-titer inhibitors. Am Health Drug Benefits. 2011 Jul; 4(4):219-31. View in: PubMed

Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study. Pediatr Blood Cancer. 2011 Jul 01; 56(7):1103-9. View in: PubMed

Pediatric catheterization laboratory anticoagulation with bivalirudin. Catheter Cardiovasc Interv. 2011 Apr 01; 77(5):671-9. View in: PubMed

New anticoagulants in children: a review of recent studies and a look to the future. Thromb Res. 2011 Feb; 127(2):70-4. View in: PubMed

Pharmacokinetic and pharmacodynamic basis for effective argatroban dosing in pediatrics. J Clin Pharmacol. 2011 Jan; 51(1):19-28. View in: PubMed

Transitioning issues in adolescent to young adult hemophilia patients with inhibitors: an approach for a growing population. Blood Coagul Fibrinolysis. 2010 Sep; 21 Suppl 1:S7-10. View in: PubMed

Comparison of kaolin and tissue factor activated thromboelastography in haemophilia. Haemophilia. 2010 May; 16(3):518-24. View in: PubMed

Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. Circulation. 2010 Apr 27; 121(16):1838-47. View in: PubMed

Off-label use of rFVIIa in children with excessive bleeding: a consecutive study of 153 off-label uses in 139 children. Pediatr Blood Cancer. 2009 Aug; 53(2):179-83. View in: PubMed

Bivalirudin for anticoagulation in children. Pediatr Blood Cancer. 2008 Dec; 51(6):798-801. View in: PubMed

Impact of inherited thrombophilia on venous thromboembolism in children: a systematic review and meta-analysis of observational studies. Circulation. 2008 Sep 23; 118(13):1373-82. View in: PubMed

Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagul Fibrinolysis. 2008 Jun; 19(4):276-82. View in: PubMed

Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia. 2008 Mar; 14(2):287-94. View in: PubMed

New anticoagulants in children. Hematology Am Soc Hematol Educ Program. 2008; 245-50. View in: PubMed

Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. Blood Coagul Fibrinolysis. 2007 Sep; 18(6):547-53. View in: PubMed

Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis. J Thromb Haemost. 2007 Aug; 5(8):1654-9. View in: PubMed

Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation. Blood Coagul Fibrinolysis. 2007 Mar; 18(2):97-103. View in: PubMed

Heparin use in children. Pediatr Res. 2007 Feb; 61(2):139-40. View in: PubMed

Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood. 2006 Jul 01; 108(1):57-62. View in: PubMed

Diagnosis and treatment of thrombosis in children: general principles. Pediatr Blood Cancer. 2006 May 01; 46(5):540-6. View in: PubMed

Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. J Pediatr. 2006 Apr; 148(4):489-94. View in: PubMed

New approaches in the management of inhibitor patients. Acta Haematol. 2006; 115(3-4):172-9. View in: PubMed

Multifocal Castleman disease in pediatrics: case report. J Pediatr Hematol Oncol. 2005 Dec; 27(12):666-9. View in: PubMed

Pediatric stroke and methylenetetrahydrofolate reductase polymorphisms: an examination of C677T and A1298C mutations. J Pediatr Hematol Oncol. 2005 Nov; 27(11):590-3. View in: PubMed

Therapy for haemophilia: recent advances and goals for the future. Expert Opin Emerg Drugs. 2005 Feb; 10(1):173-84. View in: PubMed

Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet Med. 2005 Feb; 7(2):143-6. View in: PubMed

Current and future antithrombotic agents in children. Expert Rev Cardiovasc Ther. 2004 Jul; 2(4):523-34. View in: PubMed

Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits. Perfusion. 2004; 19(5):283-8. View in: PubMed

Powered bySC CTSI